CSP—A Model for In Vivo Presentation of Plasmodium berghei Sporozoite Antigens by Hepatocytes (original) (raw)
Figure 1
Level of _Pb_CSP-specific CD8+ T-cells in different organs of BALB/C mice after treatment with either cyt c or PBS and immunization with _Pb_iSPZ.
Two groups of BALB/c mouse were pre-treated (iv through the tail vein) with 5 mg/mouse of cyt c per day for 3 days in 100 µl of PBS or with 100 µl of PBS alone. Immediately after the last treatment, mice were immunized with 1×105 _Pb_iSPZ in 100 µl of RPMI. One-week later, _Pb_CSP epitope-specific CD8+ T-cell frequency (2 mice per group of treatment) was evaluated in peripheral blood lymphocytes (PBL), liver, lymph nodes (LN) and spleen. Naïve (receiving neither cyt c, PBS nor iSPZ) mice were used as negative control. Inserted panel shows the fold change in frequency and the percentage of inhibition of _Pb_CSP-specific CD8+ T-cells in cyt c-treated compared to PBS alone-treated groups.